RxDoctor Payments Data

Jennifer Castro, NP

Nurse Practitioner · Camillus, NYNPI 1174594709

Payments from drug & device makers

$2,764in general payments, 2019–2025

Across 151 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$711
  • Novo Nordisk$388
  • GSK$233
  • Pfizer$179
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$166
  • Astellas Pharma US Inc$133
  • plus $954 from 27 others

What the payments were for

  • Food & beverage$2,764100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,764 in reported general payments places this provider in the 90th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$98,439
Medicare patients
160
Services billed
3,647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban51$49,439
JanuviaSitagliptin Phosphate19$18,374
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$17,984
XareltoRivaroxaban20$17,555
OzempicSemaglutide11$16,401
Breo ElliptaFluticasone/Vilanterol14$5,527
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate26$3,854
SymbicortBudesonide/Formoterol Fumarate15$3,266
Levothyroxine Sodium175$2,473
Atorvastatin Calcium157$2,287
Metoprolol Succinate74$1,721
Albuterol Sulfate HfaAlbuterol Sulfate63$1,456
Amlodipine Besylate175$1,266
Omeprazole72$1,132
Bupropion XlBupropion Hcl32$1,051

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$179$49,43951 claims
GSKTrelegy Ellipta, Breo Ellipta$233$23,51028 claims
MerckJanuvia$109$18,37419 claims
Johnson & JohnsonXarelto$19$17,55520 claims
Novo NordiskOzempic$388$16,40111 claims
AstraZenecaSymbicort$49$3,26615 claims
AbbVieSynthroid$711$63120 claims
Almatica Pharma LLCSertraline Hcl$37$62869 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Camillus

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →